Gulpers, B. J. A., Verhey, F. R. J., Eussen, S. J. P. M., Schram, M. T., de Galan, B. E., van Boxtel, M. P. J., Stehouwer, C. D. A., & Köhler, S. (2022). Anxiety and cognitive functioning in the Maastricht study: A cross-sectional population study. Journal of Affective Disorders, 319, 570-579. https://doi.org/10.1016/j.jad.2022.09.072

Verhulst, C. E. M., van Heck, J. I. P., Fabricius, T. W., Stienstra, R., Teerenstra, S., McCrimmon, R. J., Tack, C. J., Pedersen-Bjergaard, U., & de Galan, B. E. (2022). Sustained Pro-Inflammatory Effects of Hypoglycemia in People with Type 2 Diabetes and in People Without Diabetes. Diabetes, 71(12), 2716-2727. https://doi.org/10.2337/db22-0246

Carlton, J., Powell, P., Rowen, D., Broadley, M., Pouwer, F., Speight, J., Heller, S., Gall, M-A., Rosilio, M., Child, C. J., Comins, J., McCrimmon, R. J., de Galan, B., Brazier, J., & Hypo-RESOLVE Consortium (2022). Producing a preference-based quality of LIFE measure to quantify the impact of HYPOGLYCAEMIA on people living with diabetes: A mixed-methods research protocol. Diabetic Medicine, [e15007]. https://doi.org/10.1111/dme.15007

Jin, S., Reesink, K. D., Kroon, A. A., de Galan, B., van der Kallen, C. J. H., Wesselius, A., Schalkwijk, C. G., Stehouwer, C. D. A., & van Greevenbroek, M. M. J. (2022). Complement factors D and C3 cross-sectionally associate with arterial stiffness, but not independently of metabolic risk factors: The Maastricht Study. Journal of Hypertension, 40(11), 2161-2170. https://doi.org/10.1097/HJH.0000000000003237

Verhulst, C. E. M., Fabricius, T. W., Teerenstra, S., Kristensen, P. L., Tack, C. J., McCrimmon, R. J., Heller, S., Evans, M. L., Amiel, S. A., Pedersen-Bjergaard, U., de Galan, B. E., & Hypo-RESOLVE Consortium (2022). Glycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic review. Diabetologia, 65(10), 1601-1612. https://doi.org/10.1007/s00125-022-05749-8

Verhulst, C. E. M., Fabricius, T. W., Nefs, G., Kessels, R. P. C., Pouwer, F., Teerenstra, S., Tack, C. J., Broadley, M. M., Kristensen, P. L., McCrimmon, R. J., Heller, S., Evans, M. L., Pedersen-Bjergaard, U., & de Galan, B. E. (2022). Consistent Effects of Hypoglycemia on Cognitive Function in People With or Without Diabetes. Diabetes Care, 45(9), 2103-2110. https://doi.org/10.2337/dc21-2502

Koeneman, M., Olde Bekkink, M., Meijel, L. V., Bredie, S., & de Galan, B. (2022). Effect of Hypoglycemia on Heart Rate Variability in People with Type 1 Diabetes and Impaired Awareness of Hypoglycemia. DST Journal of Diabetes Science and Technology, 16(5), 1144-1149. https://doi.org/10.1177/19322968211007485

Divilly, P., Zaremba, N., Mahmoudi, Z., Søholm, U., Pollard, D. J., Broadley, M., Abbink, E. J., de Galan, B., Pedersen-Bjergaard, U., Renard, E., Evans, M., Speight, J., Brennan, A., McCrimmon, R. J., Müllenborn, M., Heller, S., Seibold, A., Mader, J. K., Amiel, S. A., ... Hypo-RESOLVE Consortium (2022). Hypo-METRICS: Hypoglycaemia - MEasurement, ThResholds and ImpaCtS - A multi-country clinical study to define the optimal threshold and duration of sensor-detected hypoglycaemia that impact the experience of hypoglycaemia, quality of life and health economic outcomes: the study protocol. Diabetic Medicine, 39(9), [14892]. https://doi.org/10.1111/dme.14892

Broadley, M., Chatwin, H., Søholm, U., Amiel, S. A., Carlton, J., De Galan, B. E., Hendrieckx, C., McCrimmon, R. J., Skovlund, S. E., Pouwer, F., Speight, J., & Hypo-RESOLVE Consortium (2022). The 12-Item Hypoglycemia Impact Profile (HIP12): psychometric validation of a brief measure of the impact of hypoglycemia on quality of life among adults with type 1 or type 2 diabetes. BMJ Open Diabetes Research & Care, 10(4), [e002890]. https://doi.org/10.1136/bmjdrc-2022-002890

Rebelos, E., Daniele, G., Campi, B., Saba, A., Koskensalo, K., Ihalainen, J., Saukko, E., Nuutila, P., Backes, W. H., Jansen, J. F. A., Dagnelie, P. C., Köhler, S., de Galan, B. E., van Sloten, T. T., Stehouwer, C. D. A., & Ferrannini, E. (2022). Circulating N-Acetylaspartate does not track brain NAA concentrations, cognitive function or features of small vessel disease in humans. Scientific Reports, 12(1), 11530. [11530]. https://doi.org/10.1038/s41598-022-15670-0